Affiliations: Department of Clinical Laboratory Medicine and Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, China
Correspondence:
[*]
Corresponding author: Jian-Cheng Tu, Department of Clinical Laboratory Medicine and Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, China. E-mail:jianchengtu@whu.edu.cn
Abstract: BACKGROUND: Hepatocellular carcinoma (HCC), is an extremely
aggressive malignancy with poor prognosis and high fatality rates worldwide.
Accumulating evidence indicated that novel biomarkers are required to get a
better understanding of the biological mechanisms of HCC. SRA1, a long
non-coding RNA (lncRNA), serves as a critical regulator in several cancers.
However, the association between SRA1 expression and tumorigenesis in HCC
tissues remains unclear. OBJECTIVE: In the present study, we evaluated the expression of
SRA1 in HCC and its clinical association. METHODS: The expression levels of SRA1 in 67 pairs of cancer
tissues and adjacent normal tissues from HCC patients were detected using
quantitative real-time PCR. Expression of SRA1 in HCC cell lines compared
with normal human hepatocyte cell lines was also measured. Finally, the
potential associations between its level in HCC tissues and the
clinicopathological parameters were analyzed as well. RESULTS: The results indicated that the expression levels of SRA1
in HCC were remarkably decreased, compared with matched normal tissues
(P< 0.001). Levels of SRA1 in HCC cell lines were also significantly
decreased than that in normal human hepatocyte cell line L-02. Additionally,
the levels of SRA1 were significantly associated with tumor size
(P= 0.020) and serum GLU level (P= 0.046). CONCLUSIONS: This study highlighted that SRA1 was downregulated in
HCC and might serve as a tumor suppressor in HCC, which laid a solid
foundation for future research.
Keywords: Long non-coding RNA, SRA1, HCC, down-expression
